Tadenan treatment of prostatic adenoma


Cite item

Full Text

Abstract

Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months. Home uroflowmonitoring for 1, 3, 6 and 12 months registered positive changes in urinary flow rate and urination volume. Side effects were absent. IPSS and QoL parameters were also assessed.

References

  1. Kirby R., ed. Textbook of benign prostatic hyperplasia. Oxford; 1996. 331-337.
  2. Breza J., Dzurny O., Borowka A. et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr. Med. Res. Opin. 1998; 14 (3): 127-139.
  3. Desgrandchamps F. Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia. Eur. Urol. 1997; 32 (suppl. 1): 28-31.
  4. Levin R. M., Levin S. S., Zhao Y., Buttyan R. Cellular and molecular aspects of bladder hypertrophy. Eur. Urol. 1997; 32 (suppl. 1): 15-21.
  5. Levin R. M., Das A. K. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol. Res. 2000; 28 (3): 201-209.
  6. Вишневский Е. Л. и др. Урофлоуметрия. М.: Печатный город; 2004.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies